HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arden responds to suit

This article was originally published in The Rose Sheet

Executive Summary

Lawsuit filed by The Stephan Company against Elizabeth Arden for infringing its federally registered Interlude trademark is "entirely without merit," Elizabeth Arden states in June 22 press release responding to allegations. "In fact, the U.S. Trademark Office granted Elizabeth Arden a registration for the Provocative Interlude name and will fully assert its legal rights in this matter," Arden adds. Filed in the U.S. District Court for the Southern District of New York, Stephan's suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products (1"The Rose Sheet" June 26, 2006, In Brief)...

You may also be interested in...



Suit against Arden

The Stephan Company has filed a lawsuit against Elizabeth Arden for infringing its federally registered Interlude trademark for personal care products and fragrances, company announces June 22. Filed in the U.S. District Court for the Southern District of New York, suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products, which are on sale in fine department stores. Arden launched Provocative Interlude in April (1"The Rose Sheet" April 3, 2006, Marketing In Brief). Stephan notes blocking further sales of the Provocative scent will prevent consumer confusion...

Novo Executive Calls For ‘Real AMR Action’ In Davos

The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.

Roche Gears Up For Potential Neuroscience Breakthroughs

Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.

UsernamePublicRestriction

Register

RS014038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel